 Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands February 9-11, 2023 LOS ANGELES, CA, Dec. 28, 2022 GLOBE NEWSWIRE Nexcella, Inc. Nexcella, Company, We or Us, a biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and ... The post Nexcella, Inc announces poster presentation at the European Society for Blood and Marrow Transplantation and... 